Compare RCG & VVOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RCG | VVOS |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.1M | 17.4M |
| IPO Year | 1996 | 2020 |
| Metric | RCG | VVOS |
|---|---|---|
| Price | $2.85 | $1.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.25 |
| AVG Volume (30 Days) | 13.5K | ★ 101.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 80.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,031,000.00 |
| Revenue This Year | N/A | $28.86 |
| Revenue Next Year | N/A | $48.70 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.91 |
| 52 Week Low | $2.11 | $1.42 |
| 52 Week High | $2.88 | $7.40 |
| Indicator | RCG | VVOS |
|---|---|---|
| Relative Strength Index (RSI) | 63.18 | 40.29 |
| Support Level | $2.50 | $1.42 |
| Resistance Level | N/A | $1.88 |
| Average True Range (ATR) | 0.10 | 0.14 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 96.74 | 29.90 |
RENN Fund Inc is active in the financial services domain. It is a a registered, non-diversified, closed-end management investment company formed to provide return through capital appreciation and income by a long-term, value-oriented investment process that invests in a wide variety of financial instruments, including but not limited to, common stocks, fixed-income securities including convertible and non-convertible debt securities or loans, distressed debt, warrants, and preferred stock, exchange-traded funds and exchange-traded notes, and other instruments. It invests in various industries, including communication services, surgical and medical instruments and apparatus, oil and gas, medical chemicals, botanical products, etc.
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.